KidneyCAN | Strategic Alliance Partners

Blood-based markers of note in kidney cancer prognosis include circulating tumor DNA and proteomic markers, according to Michael B. Atkins, MD.

Clinical trials still have a role in improving outcomes with immunotherapy among those with kidney cancer.

Current research initiatives in the kidney cancer field include exploring anti–PD-1, anti–LAG-3, and anti–CTLA-4 combination regimens.

The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.

Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.

Although pembrolizumab addressed a long-standing need in adjuvant kidney cancer treatment, combinations with the agent may further bolster efficacy.

Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.

Eric Jonasch, MD, believes that the Kidney Cancer Research Consortium may broaden their reach to provide care to many different groups of patients.

Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells.

Various kidney cancer trials have combined agents such as A2a receptor inhibitors with immunotherapy backbones to potentially improve treatment outcomes.

Leveraging novel agents, innovative clinical trial designs, and correlative studies may improve the treatment of patients with kidney cancer.

An “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.

Advocacy efforts have yielded a dramatic increase in kidney cancer research, according to Elizabeth P. Henske, MD.

Two oncologists discuss the impact of advocacy in kidney cancer research, highlighting collaboration between researchers, advocates, and physicians.